Claire J Han1, Kerryn Reding1, Bruce A Cooper2, Steven M Paul2, Yvette P Conley3, Marilyn Hammer4, Kord M Kober2, Jon D Levine5, Christine Miaskowski6. 1. School of Nursing, University of Washington, Seattle, Washington, USA. 2. School of Nursing, University of California, San Francisco, California, USA. 3. School of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 4. Department of Nursing, Mount Sinai Medical Center, New York, New York, USA. 5. School of Medicine, University of California, San Francisco, California, USA. 6. School of Nursing, University of California, San Francisco, California, USA. Electronic address: chris.miaskowski@ucsf.edu.
Abstract
CONTEXT: Limited evidence suggests that patients with gastrointestinal (GI) cancers receiving chemotherapy (CTX) experience an average of 13 co-occurring symptoms. An alternative to counting symptoms is to evaluate for symptom clusters. OBJECTIVES: In a sample of patients with GI cancers receiving CTX (n = 399), we evaluated the occurrence, severity, and distress of 38 symptoms in the week before patients' second or third cycle of CTX (Time 1 [T1]), approximately one week after CTX (Time 2 [T2]), and approximately two weeks after CTX (Time 3 [T3]); evaluated for differences in the number and types of symptom clusters at each of these three assessments using ratings of occurrence, severity, and distress; and evaluated for changes in symptom clusters over time. METHODS: Modified version of the Memorial Symptom Assessment Scale collected data on 38 common symptoms. Exploratory factor analyses were used to create the symptom clusters. RESULTS: Five distinct symptom clusters were identified across the three symptom dimensions and the three assessments (i.e., psychological, CTX-related, weight change, GI, and epithelial). Psychological, CTX-related, and weight change clusters were relatively stable across all three symptom dimensions and time. Across all three symptom dimensions, GI cluster was identified only at T1 and epithelial cluster was identified at T2 and T3. CONCLUSION: The number and types of symptom clusters appear to be relatively stable over time and across the symptom dimensions. Ongoing assessment and management of these clusters is warranted across the entire course of CTX. The underlying mechanism for these clusters warrants investigation.
CONTEXT: Limited evidence suggests that patients with gastrointestinal (GI) cancers receiving chemotherapy (CTX) experience an average of 13 co-occurring symptoms. An alternative to counting symptoms is to evaluate for symptom clusters. OBJECTIVES: In a sample of patients with GI cancers receiving CTX (n = 399), we evaluated the occurrence, severity, and distress of 38 symptoms in the week before patients' second or third cycle of CTX (Time 1 [T1]), approximately one week after CTX (Time 2 [T2]), and approximately two weeks after CTX (Time 3 [T3]); evaluated for differences in the number and types of symptom clusters at each of these three assessments using ratings of occurrence, severity, and distress; and evaluated for changes in symptom clusters over time. METHODS: Modified version of the Memorial Symptom Assessment Scale collected data on 38 common symptoms. Exploratory factor analyses were used to create the symptom clusters. RESULTS: Five distinct symptom clusters were identified across the three symptom dimensions and the three assessments (i.e., psychological, CTX-related, weight change, GI, and epithelial). Psychological, CTX-related, and weight change clusters were relatively stable across all three symptom dimensions and time. Across all three symptom dimensions, GI cluster was identified only at T1 and epithelial cluster was identified at T2 and T3. CONCLUSION: The number and types of symptom clusters appear to be relatively stable over time and across the symptom dimensions. Ongoing assessment and management of these clusters is warranted across the entire course of CTX. The underlying mechanism for these clusters warrants investigation.
Authors: Christine Miaskowski; Andrea Barsevick; Ann Berger; Rocco Casagrande; Patricia A Grady; Paul Jacobsen; Jean Kutner; Donald Patrick; Lani Zimmerman; Canhua Xiao; Martha Matocha; Sue Marden Journal: J Natl Cancer Inst Date: 2017-01-24 Impact factor: 13.506
Authors: Ilufredo Y Tantoy; Anand Dhruva; Janine Cataldo; Alan Venook; Bruce A Cooper; Steven M Paul; Jon D Levine; Yvette P Conley; Frances Cartwright; Kathryn Lee; Fay Wright; Christine Miaskowski Journal: J Gastrointest Oncol Date: 2017-02
Authors: Carmen W Sullivan; Heather Leutwyler; Laura B Dunn; Bruce A Cooper; Steven M Paul; Jon D Levine; Marilyn Hammer; Yvette P Conley; Christine A Miaskowski Journal: J Pain Symptom Manage Date: 2017-08-31 Impact factor: 3.612
Authors: Melissa A Frick; Carolyn C Vachani; Margaret K Hampshire; Christina Bach; Karen Arnold-Korzeniowski; James M Metz; Christine E Hill-Kayser Journal: Cancer Date: 2017-01-05 Impact factor: 6.860
Authors: Carolyn S Harris; Kord M Kober; Bruce Cooper; Yvette P Conley; Anand A Dhruva; Marilyn J Hammer; Steven Paul; Jon D Levine; Christine A Miaskowski Journal: Support Care Cancer Date: 2022-05-11 Impact factor: 3.603
Authors: Carolyn S Harris; Kord M Kober; Yvette P Conley; Anand A Dhruva; Marilyn J Hammer; Christine A Miaskowski Journal: BMJ Support Palliat Care Date: 2021-12-17 Impact factor: 3.568
Authors: Rachel A Pozzar; Marilyn J Hammer; Bruce A Cooper; Kord M Kober; Lee-May Chen; Steven M Paul; Yvette P Conley; Frances Cartwright; Fay Wright; Jon D Levine; Christine Miaskowski Journal: Cancer Nurs Date: 2021-09-23 Impact factor: 2.760
Authors: Yufen Lin; Donald E Bailey; Sharron L Docherty; Laura S Porter; Bruce A Cooper; Steven M Paul; Kord M Kober; Marilyn J Hammer; Fay Wright; Laura B Dunn; Yvette P Conley; Jon D Levine; Christine Miaskowski Journal: Support Care Cancer Date: 2021-01-16 Impact factor: 3.359